Case Study: PharmChem, Inc. (OTC: PCHM) - Demystifying MicroCap Myths

On this episode of Avoiding the Crowd with Maj Soueidan, there are many myths around MicroCap Stocks that many investors use as excuses to not invest in this asset class - not enough liquidity, usually little to no revenues, poor quality management teams, no dividend; the list goes on. We thought it would be fun to use a case study on a company that demystifies some of these myths - one that has been a very successful investment for Maj. Using his investing experience in PharmChem, Inc. (OTC: PCHM), which he still owns, Maj demonstrates how a non-fully reporting, revenue generating, profitable, dividend paying, illiquid OTC company with a stop sign has worked out for his portfolio. Please enjoy!

For more information about GeoInvesting.com, and their Premium MicroCap Research service, start your 7-day Free Trial here: https://geoinvesting.com/

Every week, Maj will be sharing his latest insights and ideas covering the most overlooked asset class, MicroCap Stocks. From latest observations to portfolio strategies to stock ideas, Maj leverages his 30 years of MicroCap investing experience to help you on your investing journey.

This podcast is brought to you by SNN Network. All shows can be found wherever you listen to podcasts, as well as on SNN Network's YouTube Channel, subscribe here: bit.ly/1Q5Yfym

You can Follow SNN Network on Twitter @BobbyKKraft

You can Follow Maj Soueidan on Twitter @MajGeoinvesting

This podcast is for informational purposes only and is not an offer or solicitation of an offer to buy or sell securities. SNN Network and Maj Soueidan are not licensed brokers, broker/dealers, market makers, investment bankers, investment advisers, analysts, or underwriters. We do not recommend any companies discussed. We may buy, sell, short, cover securities in any company mentioned and may profit in the event those securities rise in value if we are long, and fall if we are short. We recommend you consult with a professional investment adviser, broker, or legal counsel before purchasing or selling any securities referenced in this podcast.